Open Access

Accelerated elimination of human cancer cells by a CD40 agonist antibody combined with a PD‑1 antagonist in CD4‑depleted mice

  • Authors:
    • Soon‑Hyun Ahn
    • Joo Yeon Choi
    • Seong Dong Kim
    • Sung Joon Park
    • Hyojin Kim
  • View Affiliations

  • Published online on: October 14, 2019     https://doi.org/10.3892/ol.2019.10991
  • Pages: 5889-5896
  • Copyright: © Ahn et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The elimination of residual microscopic cancer cells is important cancer treatment. The immunoediting theory describes the balance between the immune system and cancer cells. The current study investigated changes in the immune system during the elimination of cancer cells and evaluated the influence of cluster of differentiation (CD)4 or CD8 depletion. A human squamous cell cancer cell line (SNU1041) was injected in the lateral tongue of immunocompetent mice and the changes in the CD4, CD8, CD11b, CD19, CD40 and CD40 ligand (L) populations in the blood, lymph nodes and spleen were evaluated using flow cytometry, and changes in serum cytokine levels were evaluated using a magnetic bead panel. Cancer cell elimination was delayed by CD4 depletion but not by CD8 depletion. The CD8‑depleted group indicated increased levels of CD40L, interferon‑gamma, interleukin (IL)‑10, IL‑6, and tumor necrosis factor‑α. It was concluded that CD4 served a crucial role in the elimination of human cancer cells. Furthermore, the efficacies of CD40 agonist and programmed cell death protein 1 (PD1) antagonist treatments were assessed in CD4‑depleted mice. CD40 agonist treatment resulted in faster cancer cell elimination and increased cytokine excretion. In conclusion, CD4 or CD40L significantly influenced cancer elimination. CD40 agonist antibodies may be potent adjuvant agents that can be used in patients with reduced CD4 or CD40L expression

Related Articles

Journal Cover

December 2019
Volume 18 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Ahn, S., Choi, J.Y., Kim, S.D., Park, S.J., & Kim, H. (2019). Accelerated elimination of human cancer cells by a CD40 agonist antibody combined with a PD‑1 antagonist in CD4‑depleted mice. Oncology Letters, 18, 5889-5896. https://doi.org/10.3892/ol.2019.10991
MLA
Ahn, S., Choi, J. Y., Kim, S. D., Park, S. J., Kim, H."Accelerated elimination of human cancer cells by a CD40 agonist antibody combined with a PD‑1 antagonist in CD4‑depleted mice". Oncology Letters 18.6 (2019): 5889-5896.
Chicago
Ahn, S., Choi, J. Y., Kim, S. D., Park, S. J., Kim, H."Accelerated elimination of human cancer cells by a CD40 agonist antibody combined with a PD‑1 antagonist in CD4‑depleted mice". Oncology Letters 18, no. 6 (2019): 5889-5896. https://doi.org/10.3892/ol.2019.10991